GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (FRA:SMZ1) » Definitions » PB Ratio

Sino Biopharmaceutical (FRA:SMZ1) PB Ratio : 1.72 (As of Dec. 15, 2024)


View and export this data going back to . Start your Free Trial

What is Sino Biopharmaceutical PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-12-15), Sino Biopharmaceutical's share price is €0.3982. Sino Biopharmaceutical's Book Value per Share for the quarter that ended in Jun. 2024 was €0.23. Hence, Sino Biopharmaceutical's PB Ratio of today is 1.72.

The historical rank and industry rank for Sino Biopharmaceutical's PB Ratio or its related term are showing as below:

FRA:SMZ1' s PB Ratio Range Over the Past 10 Years
Min: 1.29   Med: 5.71   Max: 13.22
Current: 1.7

During the past 13 years, Sino Biopharmaceutical's highest PB Ratio was 13.22. The lowest was 1.29. And the median was 5.71.

FRA:SMZ1's PB Ratio is ranked better than
64.64% of 1281 companies
in the Biotechnology industry
Industry Median: 2.48 vs FRA:SMZ1: 1.70

During the past 12 months, Sino Biopharmaceutical's average Book Value Per Share Growth Rate was 11.40% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 19.90% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 21.90% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 20.50% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Sino Biopharmaceutical was 75.30% per year. The lowest was -30.70% per year. And the median was 18.35% per year.

Back to Basics: PB Ratio


Sino Biopharmaceutical PB Ratio Historical Data

The historical data trend for Sino Biopharmaceutical's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical PB Ratio Chart

Sino Biopharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.94 6.88 2.66 2.54 1.86

Sino Biopharmaceutical Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.46 2.54 2.10 1.86 1.37

Competitive Comparison of Sino Biopharmaceutical's PB Ratio

For the Biotechnology subindustry, Sino Biopharmaceutical's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sino Biopharmaceutical's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's PB Ratio distribution charts can be found below:

* The bar in red indicates where Sino Biopharmaceutical's PB Ratio falls into.



Sino Biopharmaceutical PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Sino Biopharmaceutical's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Jun. 2024)
=0.3982/0.231
=1.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Sino Biopharmaceutical  (FRA:SMZ1) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Sino Biopharmaceutical PB Ratio Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sino Biopharmaceutical Business Description

Traded in Other Exchanges
Address
1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG
Listed on the Hong Kong Stock Exchange in 2000, Sino Biopharmaceutical is one of the largest Chinese drugmakers. It started with generic drug manufacturing. Since 2018, Sino Biopharm has been actively pivoting into an innovative drugmaker after the Chinese government launched its volume-based procurement policy for the healthcare industry. As of 2023, 37.8% of the firm's total revenue comes from five innovative drugs and five biosimilar drugs. Sino Biopharm's biggest revenue segment is oncology medicines, accounting for 33.6% of total revenue, followed by hepatitis, surgery/analgesia, respiratory, and cardio-cerebral vascular therapeutic areas.

Sino Biopharmaceutical Headlines

No Headlines